- Home
- EQS vs CYCN Comparison
EQS vs CYCN Comparison
Compare EQS & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EQS | CYCN |
|---|---|---|
| Founded | 1991 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.2M | 16.6M |
| IPO Year | 1995 | 2019 |
Fundamental Metrics
Financial Performance| Metric | EQS | CYCN |
|---|---|---|
| Price | $1.01 | $3.88 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 7.5K | ★ 36.0K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.26 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,074,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.70 |
| 52 Week Low | $1.01 | $1.03 |
| 52 Week High | $2.49 | $8.48 |
Technical Indicators
Market Signals| Indicator | EQS | CYCN |
|---|---|---|
| Relative Strength Index (RSI) | 38.47 | 58.67 |
| Support Level | N/A | $2.93 |
| Resistance Level | $2.03 | $4.47 |
| Average True Range (ATR) | 0.05 | 0.38 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 15.79 | 56.17 |
Price Performance
Historical ComparisonAbout EQS Equus Total Return Inc.
Equus Total Return Inc is a United States-based closed-end management investment company. The company invests mainly in companies pursuing growth either through acquisition or organically, leveraged buyouts, management buyouts, and recapitalizations of existing businesses or special situations, and achieves capital appreciation by making investments in equity and equity-oriented securities issued by privately-owned companies or smaller public companies in transactions.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. The company focuses on enabling the full therapeutic potential of next-generation sGC stimulators and neuropsychiatric diseases. Its pipeline products include Olinciguat, Praliciguat, and others.